MX2020003096A - Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif. - Google Patents

Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.

Info

Publication number
MX2020003096A
MX2020003096A MX2020003096A MX2020003096A MX2020003096A MX 2020003096 A MX2020003096 A MX 2020003096A MX 2020003096 A MX2020003096 A MX 2020003096A MX 2020003096 A MX2020003096 A MX 2020003096A MX 2020003096 A MX2020003096 A MX 2020003096A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
hydroxylase inhibitor
hif hydroxylase
hif
inhibitor
Prior art date
Application number
MX2020003096A
Other languages
English (en)
Inventor
Claudia Witschi
David Conca
Lee Allen Flippin
Scott David Leigh
Lee Robert Wright
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020003096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of MX2020003096A publication Critical patent/MX2020003096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a formulaciones farmacéuticas del ácido [(4-hidroxi-1-metil-7-fenoxi-isoquinolina-3-carbonil)-am ino]-acético y métodos de uso de los mismos.
MX2020003096A 2013-06-06 2015-12-01 Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif. MX2020003096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361831909P 2013-06-06 2013-06-06

Publications (1)

Publication Number Publication Date
MX2020003096A true MX2020003096A (es) 2020-08-17

Family

ID=51063834

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015016536A MX2015016536A (es) 2013-06-06 2014-06-05 Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif.
MX2020003096A MX2020003096A (es) 2013-06-06 2015-12-01 Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
MX2022011225A MX2022011225A (es) 2013-06-06 2015-12-01 Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015016536A MX2015016536A (es) 2013-06-06 2014-06-05 Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011225A MX2022011225A (es) 2013-06-06 2015-12-01 Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.

Country Status (24)

Country Link
US (3) US20160120859A1 (es)
EP (2) EP3003284B1 (es)
JP (4) JP6604941B2 (es)
KR (3) KR20210104173A (es)
CN (5) CN110448537A (es)
AU (1) AU2014274890B2 (es)
CA (1) CA2914049C (es)
CY (1) CY1122951T1 (es)
DK (1) DK3003284T3 (es)
ES (1) ES2786924T3 (es)
HK (1) HK1222550A1 (es)
HR (1) HRP20200615T1 (es)
HU (1) HUE049623T2 (es)
IL (3) IL298998B1 (es)
LT (1) LT3003284T (es)
ME (1) ME03777B (es)
MX (3) MX2015016536A (es)
PL (1) PL3003284T3 (es)
PT (1) PT3003284T (es)
RS (1) RS60464B1 (es)
SG (1) SG11201509764RA (es)
SI (1) SI3003284T1 (es)
WO (1) WO2014197660A1 (es)
ZA (1) ZA201508712B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1644336T3 (pl) 2003-06-06 2011-07-29 Fibrogen Inc Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny
US8927591B2 (en) 2008-11-14 2015-01-06 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
ES2631655T3 (es) 2012-07-16 2017-09-01 Fibrogen, Inc. Procedimiento para fabricar compuestos de isoquinolina
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SI3470397T1 (sl) 2012-07-16 2022-07-29 Fibrogen, Inc. Kristalinične oblike zaviralca prolil hidroksilaze
DK3003284T3 (da) 2013-06-06 2020-03-30 Fibrogen Inc Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor
BR112017021097B1 (pt) * 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
CN111065625A (zh) * 2017-09-04 2020-04-24 桑多斯股份公司 口服可利用的hif脯氨酰羟化酶抑制剂的共晶
CN110664814A (zh) * 2019-10-24 2020-01-10 上海长海医院 Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) * 2019-12-17 2022-08-19 河北长天药业有限公司 一种复方氨酚那敏颗粒
EP4121009A4 (en) * 2020-03-17 2024-04-17 Zydus Lifesciences Limited FORMULATION COMPRISING HIF PROLYL HYDROXYLASE INHIBITORS
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
CN114796280B (zh) * 2022-06-15 2024-06-25 河北长天药业有限公司 一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) * 2022-08-08 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. An oral pharmaceutical composition comprising roxadustat

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US20030176317A1 (en) 2001-12-06 2003-09-18 Volkmar Guenzler-Pukall Stabilization of hypoxia inducible factor (HIF) alpha
US8318703B2 (en) * 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
DE10209692A1 (de) 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
JP4805234B2 (ja) * 2002-12-16 2011-11-02 キッセイ薬品工業株式会社 経口固形医薬
MXPA05006513A (es) 2002-12-16 2005-09-08 Kissei Pharmaceutical Farmaco solido para uso oral.
PL1644336T3 (pl) * 2003-06-06 2011-07-29 Fibrogen Inc Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
KR101194123B1 (ko) 2004-03-16 2012-10-24 아사히 가세이 파마 가부시키가이샤 패수딜 함유 제제 및 그 안정성을 개선하는 방법
JP4792048B2 (ja) 2005-03-02 2011-10-12 ファイブロゲン インコーポレイティッド チエノピリジン化合物およびその使用方法
JP5390184B2 (ja) 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
CN101242817B (zh) 2005-06-15 2016-08-31 菲布罗根公司 HIF1α调节剂在治疗癌症中的用途
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
ES2375643T3 (es) 2005-10-31 2012-03-02 Kowa Company, Ltd. Preparación farmacéutica que presenta excelente fotoestabilidad.
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
MX2008009581A (es) 2006-01-27 2009-01-07 Fibrogen Inc Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih).
WO2007092031A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
CN101420980A (zh) 2006-02-16 2009-04-29 菲布罗根公司 治疗中风的化合物和方法
MX2008012734A (es) 2006-04-04 2009-01-29 Fibrogen Inc Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif).
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
TW200924768A (en) 2007-10-12 2009-06-16 Astrazeneca Ab Composition
WO2009058403A1 (en) 2007-11-02 2009-05-07 Fibrogen, Inc. Methods for reducing blood pressure
EP2227475B1 (en) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009075824A1 (en) 2007-12-06 2009-06-18 Fibrogen, Inc. Methods for increasing endothelial progentior cells
US20110039879A1 (en) 2007-12-07 2011-02-17 FibroGen ,Inc. Methods for increasing white blood cells
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
EP2334682B1 (en) 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
US20110263642A1 (en) 2008-08-26 2011-10-27 Fibrogen, Inc. Methods for treatment of multiple sclerosis
US8927591B2 (en) 2008-11-14 2015-01-06 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
US20100144737A1 (en) 2008-12-08 2010-06-10 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
JP5591128B2 (ja) 2009-01-29 2014-09-17 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
WO2012097329A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing mean corpuscular volume
WO2012097331A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
US8921389B2 (en) 2011-02-02 2014-12-30 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
JP6099644B2 (ja) 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
WO2013070908A1 (en) * 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
US9409892B2 (en) 2012-03-09 2016-08-09 Fibrogen, Inc. 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
ES2631655T3 (es) 2012-07-16 2017-09-01 Fibrogen, Inc. Procedimiento para fabricar compuestos de isoquinolina
SI3470397T1 (sl) 2012-07-16 2022-07-29 Fibrogen, Inc. Kristalinične oblike zaviralca prolil hidroksilaze
KR102233081B1 (ko) 2013-01-24 2021-03-29 피브로겐, 인크. 〔[1-시아노-5-(4-클로로페녹시)-4-하이드록시-아이소퀴놀린-3-카보닐]-아미노〕-아세트산의 결정 형태
DK3003284T3 (da) 2013-06-06 2020-03-30 Fibrogen Inc Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor

Also Published As

Publication number Publication date
KR20220164069A (ko) 2022-12-12
SI3003284T1 (sl) 2020-08-31
US20190008846A1 (en) 2019-01-10
US20160120859A1 (en) 2016-05-05
NZ754196A (en) 2021-06-25
SG11201509764RA (en) 2015-12-30
RU2015151056A3 (es) 2018-05-03
MX2015016536A (es) 2016-08-11
IL242759B2 (en) 2023-05-01
EP3003284B1 (en) 2020-02-12
CN110448537A (zh) 2019-11-15
KR20160018514A (ko) 2016-02-17
JP2021100971A (ja) 2021-07-08
WO2014197660A1 (en) 2014-12-11
EP3708154A1 (en) 2020-09-16
KR102291860B1 (ko) 2021-08-20
ZA201508712B (en) 2020-07-29
US20220054474A1 (en) 2022-02-24
LT3003284T (lt) 2020-04-27
IL242759B1 (en) 2023-01-01
RU2015151056A (ru) 2017-07-14
CN111728950A (zh) 2020-10-02
IL298998B1 (en) 2024-03-01
CY1122951T1 (el) 2021-10-29
CA2914049C (en) 2021-10-12
MX2022011225A (es) 2022-10-07
CN105377242A (zh) 2016-03-02
CN111728951A (zh) 2020-10-02
RU2681304C2 (ru) 2019-03-06
BR112015029693A8 (pt) 2019-12-24
CN111728952A (zh) 2020-10-02
ME03777B (me) 2021-04-20
AU2014274890B2 (en) 2019-10-03
HK1222550A1 (zh) 2017-07-07
PL3003284T3 (pl) 2020-08-10
EP3003284A1 (en) 2016-04-13
IL242759A (es) 2015-12-31
JP6604941B2 (ja) 2019-11-13
JP2016523846A (ja) 2016-08-12
US10765672B2 (en) 2020-09-08
CA2914049A1 (en) 2014-12-11
BR112015029693A2 (pt) 2017-07-25
DK3003284T3 (da) 2020-03-30
HUE049623T2 (hu) 2020-09-28
AU2014274890A1 (en) 2015-12-17
IL296484A (en) 2022-11-01
KR20210104173A (ko) 2021-08-24
JP2023068197A (ja) 2023-05-16
RS60464B1 (sr) 2020-07-31
HRP20200615T1 (hr) 2020-07-10
JP2019137703A (ja) 2019-08-22
IL298998A (en) 2023-02-01
JP6861758B2 (ja) 2021-04-21
PT3003284T (pt) 2020-08-10
NZ714554A (en) 2021-06-25
ES2786924T3 (es) 2020-10-14

Similar Documents

Publication Publication Date Title
MX2020003096A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EA201691582A1 (ru) Новые фармацевтические препараты
AR095977A1 (es) Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
IN2012DE00912A (es)
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
GT201300003A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion , y las composiciones farmacèuticas que la contienen
MX2015016490A (es) Esteres sulfatados de acidos oligohidroxicarboxilicos, y uso de los mismos.
IN2013MU01111A (es)
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
EP2948143A4 (en) Use of phenoxypropylamine compounds to treat depression
IN2015DN03114A (es)
PT3075738T (pt) Derivado de ácido glicirretínico e utilização do mesmo
IN2013CH03945A (es)
BR112015029622A2 (pt) pigmentos ácidos, processos para sua produção e seu uso
MX2016007130A (es) Nuevo procedimiento de sintesis del 7-metoxi-naftaleno-1-carbaldeh ido y aplicacion en la sintesis de la agomelatina.
IN2013MU02279A (es)
UY33803A (es) Formas de dosificación de liberación modificada novedosas de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa
RU2012144184A (ru) Применение препаратов гуминовых кислот в качестве ингибиторов липазы